1 completed, 1 terminated. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Rapidly progressive glomerulonephritis with pulmonary hemorrhage: new trials by email Literature Review of Rapidly progressive glomerulonephritis with pulmonary hemorrhage trials Research Report on Rapidly progressive glomerulonephritis with pulmonary hemorrhage
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study With Imlifidase in Anti-GBM Disease Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC) - Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease | Phase 3 | Terminated | Hansa Biopharma AB | 50 | 2022-12-22 | 2026-03-04 |
| Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease Imlifidase - Anti-Glomerular Basement Membrane Antibody Disease | Phase 2 | Completed | Mårten Segelmark | 15 | 2017-06-16 | 2022-04-07 |
Anti-Glomerular Basement Membrane Disease (1)
Autoimmune Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Glomerulonephritis (1) · Immune System Diseases (1) · Kidney Diseases (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Male Urogenital Diseases (1) · Nephritis (1) · Respiratory Tract Diseases (1) · Urogenital Diseases (1) · Urologic Diseases (1)
Mac-1-like protein, Streptococcus (2) · Cyclophosphamide (1) · Glucocorticoids (1) · Plasma Exchange (1)
Hansa Biopharma AB (1) · Mårten Segelmark (1)
Austria (2) · Czechia (2) · Denmark (2) · France (2) · Sweden (2) · Belgium (1) · Germany (1) · Ireland (1) · Italy (1) · Netherlands (1) · Spain (1) · United Kingdom (1) · United States (1)